CA Patent

CA2904270A1 — Protein kinase inhibitors

Assigned to GB005 Inc · Expires 2017-03-11 · 9y expired

What this patent protects

Compounds having the Formula l, and enantiomers, diastereomers, pharmaceutically acceptable salts, solvates and solvates of salts thereof, (see Formula I) are useful as kinase inhibitors or modulators, including BTK modulation or inhibition, wherein X1, X2, m, m', E and R1 are as…

USPTO Abstract

Compounds having the Formula l, and enantiomers, diastereomers, pharmaceutically acceptable salts, solvates and solvates of salts thereof, (see Formula I) are useful as kinase inhibitors or modulators, including BTK modulation or inhibition, wherein X1, X2, m, m', E and R1 are as defined herein.

Drugs covered by this patent

Patent Metadata

Patent number
CA2904270A1
Jurisdiction
CA
Classification
—
Expires
2017-03-11
Drug substance claim
No
Drug product claim
No
Assignee
GB005 Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.